Featured
Addressing Assessment and Access Issues for Rare Diseases
With the promise of more rare disease treatments on the horizon (particularly genetic treatments for hemophilia and sickle cell disease, which promise to be “one and done” therapies), their much higher per patient cost will create market access and other challenges to payers, providers, and patients.ISSUE HIGHLIGHTS
COLUMNS
HEOR Articles
The Role of Education in Shaping an Open-Source Future
By the Numbers
HEOR & Rare Diseases
Research Roundup
Research Roundup
HEOR News
HEOR News
ISPOR Conferences
ISPOR Conferences and EventsLatest News
Rethinking Value Assessment for Orphan Drugs
Dec 18, 2024
ISPOR Launches “HEOR Explained” Microsite
Dec 10, 2024
